# A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

> **NCT04591262** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 14C-PF-06826647-LR 600 mg PO
- **DRUG:** PF-06826647 600 mg PO
- **DRUG:** 14C-PF-06826647 100 ug IV

## Key facts

- **NCT ID:** NCT04591262
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2021-01-28
- **Final completion:** 2021-01-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591262, "A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04591262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*